Attenuated Leishmania major Induce a High Level of Protec-tion against Leishmania infantum in BALB/c Mice

  • Shamsi NOORPISHEH GHADIMI Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Leila HOMAYOON Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Reza SHAHRIARIRAD Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
  • Shakila FATEHPOUR Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mohammad RASTEGARIAN Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
  • Bahador SARKARI Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Keywords: Attenuated L. major, L. infantum, Cross-protection

Abstract

Background: The current study aimed to investigate the possible cross-protective effects of attenuated L. major against L. infantum in BALB/c mice. Methods: This experimental study was performed in 2017 in Shiraz University of Medical Sciences, Shiraz, Iran. The attenuated strain of L. major was prepared by continuous weekly subculturing of the parasite. Forty-eight female BALB/c mice were divided into eight groups. Group 1 injected (ID) with wild type of L. major; group 2 injected (IV) with L. infantum; group 3 injected (ID) with attenuated L. major; group 4 injected (ID) with attenuated L. major, and after three weeks challenged (IV) with L. infantum; group 5 injected (IP) with attenuated L. major; group 6 injected (IP) with attenuated L. major, and challenged (IV) with L. infantum (IV); group 7 injected (IV) with attenuated L. major; and finally group 8 injected (IV) with attenuated L. major and after three weeks challenged (IV) with L. infantum. Forty-five days post-infection, the parasite load in the spleen and liver of the mice was determined as Leishman-Donovan units (LDU). Results: The differences in mean of LDU of spleen between different groups were statistically significant (P<0.048). In addition, the differences in percent of infection in liver between pairwise comparisons of groups were statistically significant (P<0.05). The highest intensity of infection was observed in group 2 while low intensity of infection was seen in groups 3, 4 and 5. Conclusion: Live attenuated L. major can induce substantial protection against L. infantum, particularly when the parasites were injected intravenously.

References

1. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
2. Mohebali M. Visceral leishmaniasis in Iran: Review of the epidemiological and clinical features. Iran J Parasitol. 2013;8(3):348-58.
3. Davami MH, Motazedian MH, Sarkari B. The changing profile of cutaneous leishmaniasis in a focus of the disease in Jahrom district, southern Iran. Ann Trop Med Parasitol. 2010 J;104(5):377-82.
4. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis. 2010;2(2):177-85.
5. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, Menz I, Palatnik M, Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine. 2009;27(27):3505-12.
6. Mohammadi-Ghalehbin B, Hatam G, Sarkari B et al. Cytokine profile of Leishmania infantum fucose-mannose ligand in vaccinated dogs in the Northwest of Iran. Iran J Immunol. 2017;14(4):293-305.
7. Sarkari B, Pedram N, Mohebali M et al. Seroepidemiological study of visceral leishmaniasis in Booyerahmad district, south-west Islamic Republic of Iran. East Mediterr Health J. 2010; 16(11):1133-6.
8. Sarkari B, Ahmadpour NB, Motazedian MH et al. Inter- and intraspecific variations of Leishmania strains isolated from patients with cutaneous and visceral leishmaniases in Fars Province, South of Iran. Iran J Med Sci. 2016;41(3):209-16.
9. Sarkari B, Gadami F, Shafiei R et al. Seroprevalence of Leishmania infection among the healthy blood donors in kala-azar endemic areas of Iran. J Parasit Dis. 2015;39(3):545-9.
10. Sharifi I, Aflatoonian MR, Daei Parizi MH et al. Visceral leishmaniasis in Southeastern Iran: A narrative review. Iran J Parasitol. 2017;12(1):1-11.
11. Sarkari B, Naraki T, Ghatee MA et al. Visceral leishmaniasis in Southwestern Iran: A retrospective clinico-hematological analysis of 380 consecutive hospitalized cases (1999-2014). PLoS One. 2016;11(3):e0150406.
12. Selvapandiyan A, Dey R, Nylen S et al. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol. 2009;183(3):1813-20.
13. Goto Y, Bhatia A, Raman VS et al. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine. 2009;27(21):2884-90.
14. Porrozzi R, Teva A, Amaral VF et al. Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta). Am J Trop Med Hyg. 2004;71(3):297-305.
15. Moreira D, Santarém N, Loureiro I et al. Impact of continuous axenic cultivation in Leishmania infantum virulence. PLoS Negl Trop Dis. 2012;6(1):e1469.
16. Foroughi-Parvar F, Hatam G-R, Sarkari B, Kamali-Sarvestani E. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis. Immunotherapy. 2015;7(1):3-12.
17. Hatam G, Rezanezhad H, Motazedian M, Sarkari B. In vitro infectivity of Leishmania major isolated from patients with different clinical forms of cutaneous leishmaniasis and its association with parasite zymodems. Iran J Parasitol. 2009;4(3):52-60.
18. Chamakh-Ayari R, Chenik M, Chakroun AS et al. Leishmania major large RAB GTPase is highly immunogenic in individuals immune to cutaneous and visceral leishmaniasis. Parasit Vectors. 2017;10(1):185.
19. Nico D, Claser C, Borja-Cabrera GP et al. Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell–driven protective response. PLoS Negl Trop Dis. 2010;4(11):e866.
20. Nico D, Gomes DC, Alves-Silva MV et al. Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains. Front Immunol. 2014; 1;5:189.
21. Chakravarty J, Kumar S, Trivedi S et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+ MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011;29(19):3531-7.
22. Kima PE, Soong L. Interferon gamma in leishmaniasis. Front Immunol. 2013;4:156.
23. Howard JG, Liew FY, Hale C, Nicklin S. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J Immunol. 1984;132(1):450-5.
24. Gicheru MM, Olobo JO, Anjili CO. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp Parasitol. 1997;85(2):109-16.
Published
2019-06-19
How to Cite
1.
NOORPISHEH GHADIMI S, HOMAYOON L, SHAHRIARIRAD R, FATEHPOUR S, RASTEGARIAN M, SARKARI B. Attenuated Leishmania major Induce a High Level of Protec-tion against Leishmania infantum in BALB/c Mice. Iran J Parasitol. 14(2):310-317.
Section
Original Article(s)